Skip to main content
NewslettersWatchlist

Outlook Therapeutics Inc(OTLK-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Outlook Therapeutics Inc

111 S. WOOD AVENUE UNIT #100
ISELIN NJ 08830 USA
P: 609-619-3990
http://www.outlooktherapeutics.com

Profile

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.

Key Executives

NameTitle
Lawrence A. KenyonCFO/Chief Accounting Officer/Director/Executive VP/Secretary/Treasurer
Jeff EvansonOther Executive Officer
C. Russell TrenaryCEO/Director/President

More from The Globe

Dividend investing has lost its mojo. Here’s why – and how to adapt
Ian McGugan
The Globe Investing Club 2024: Let the competition begin!
opinion
Here’s the real reason your Canadian stocks can’t keep up
Tim Shufelt
Dow ends above 40,000 milestone, TSX also at fresh record high
Traders work on the floor of the New York Stock Exchange (NYSE) on May 16.
number cruncher
U.S technology stocks with earnings and price momentum
For Number Cruncher column in Globe Investor/ROB only.
Lightspeed Commerce stock soars on better-than-expected profit forecast
Lightspeed Commerce Inc. CEO Dax Dasilva poses in the company's offices in Montreal, Wednesday, May 8, 2024. THE CANADIAN PRESS/Christinne Muschi
GameStop, AMC dive further as meme stocks rally tapers off
A screen displays the trading information for GameStop and AMC Theatres on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., May 15.
The close: Dow briefly hits 40,000 milestone, TSX rises on upbeat earnings
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Financial data provided by Zacks Investment Research.